Cardiome Pharma
Cardiome Pharma operates the cardiome.com domain, which displays only a 'Launching Soon' placeholder page with a 2025 copyright notice. The name suggests an intended focus on cardiovascular pharmaceuticals, but no products, customers, team, funding, or operations are documented in available data.
- Company typePrivate
- Founded1986
- HeadquartersVancouver, Canada
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Cardiome Pharma does
Cardiome Pharma is an entity operating under the cardiome.com web domain that, based on available input data, presents itself as a pharmaceutical company oriented toward the cardiovascular therapeutic area (as suggested by the 'Cardiome' naming convention combining 'cardio' and 'ome'). The company has not yet disclosed any operational substance: its website is a placeholder 'Launching Soon' page with only a 2025 copyright notice, a 'Contact Us' prompt, and a standard cookie consent banner. No products, pipeline assets, technology stack, regulatory filings, certifications, leadership team, headcount, funding history, partnerships, customer references, operating geographies, or revenue figures are documented in the input data.
Because the source material is limited to a single placeholder webpage, the company's actual business model, core products, underlying technology, pricing mechanics, go-to-market strategy, and customer segments cannot be verified from the available evidence. It is unknown whether Cardiome Pharma is a newly formed entity preparing to launch, a previously operating company undergoing a relaunch, a shell brand, or an entity whose substantive information simply has not been captured in the scraped source set. The only resolvable source ID consistently attributes the 'Launching Soon' placeholder observation to the cardiome.com landing page itself.
From an analytical standpoint, the company should be treated as a pre-commercial or pre-disclosure-stage entity pending further evidence. Any investment-grade conclusions about therapeutic focus, pipeline quality, regulatory pathway, commercial viability, or capital structure require confirmation from primary sources beyond the placeholder website, including clinical pipelines, FDA/EMA filings, investor disclosures, or corporate registries.
Cardiome Pharma firmographics
Firmographics- Name
- Cardiome Pharma
- Legal name
- Not determinable from available source data
- Website
- https://cardiome.com
- Company type
- Private
- Founded year
- 1986
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cardiome Pharma operates the cardiome.com domain, which displays only a 'Launching Soon' placeholder page with a 2025 copyright notice. The name suggests an intended focus on cardiovascular pharmaceuticals, but no products, customers, team, funding, or operations are documented in available data.
- Ownership category
- akta.pro rank
Where Cardiome Pharma is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Markets served
Cardiome Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
Cardiome Pharma product offering
Product offeringCore offering
The cardiome.com website displays only a "Launching Soon" placeholder page. No core offerings, products, or services are evidenced in the available source data.
Differentiator
Problem solved
Functional benefit
Cardiome Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cardiome Pharma partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights1 record
Cardiome Pharma competitors and assessment
Company assessmentDirect peers
- Lexicon Pharmaceuticals: Biopharmaceutical company developing treatments for cardiovascular and metabolic diseases. Comparable as a developer targeting overlapping cardio-metabolic indications with a specialty-pharma profile.
- Madrigal Pharmaceuticals: Clinical-stage biopharmaceutical company focused on cardio-metabolic and liver disease, with commercialized cardiovascular-relevant therapy. Comparable as a specialty pharma with therapeutic focus intersecting cardiovascular and metabolic disease.
- Cytokinetics: Late-stage specialty biopharmaceutical company developing cardiac muscle biology-directed therapies for heart failure and related cardiovascular conditions. Comparable as a focused cardiac-muscle therapeutic developer in the cardiology space.
- Esperion Therapeutics: Specialty cardiovascular pharmaceutical company focused on lipid management and cardiometabolic disease, with commercialized oral therapies. Highly comparable as a focused, public cardio-pharma entity targeting established cardiovascular indications.
Emerging players
- Tenaya Therapeutics: Clinical-stage biotechnology company focused on cardiac gene therapy and related regenerative approaches for heart disease. Comparable as a development-stage player working in the cardiology therapeutic space, though using a different modality.
Broad incumbents
- Bayer (Cardiovascular Division): Major pharmaceutical company with an established cardiovascular franchise (e.g., Xarelto/rivaroxaban). Comparable as a broad incumbent operating in the cardiology space where a focused specialty entrant would compete or partner.
Market position
Strengths2 records
Weaknesses3 records
Key risks4 records
Key highlights2 records
Customer concentration
Cardiome Pharma social profiles
Digital presenceCardiome Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cardiome Pharma leadership team
Management profileNumber of profiles
Cardiome Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cardiome Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cardiome Pharma
What does Cardiome Pharma do?
The cardiome.com website displays only a "Launching Soon" placeholder page. No core offerings, products, or services are evidenced in the available source data.
When was Cardiome Pharma founded?
Cardiome Pharma was founded in 1986. It employs 51 to 100 people.
Where is Cardiome Pharma based?
Cardiome Pharma is headquartered in Vancouver, Canada, in the North America region.
Who are Cardiome Pharma's main competitors?
Direct peers on record are Lexicon Pharmaceuticals, Madrigal Pharmaceuticals, Cytokinetics and Esperion Therapeutics. Tenaya Therapeutics is listed as an emerging player. Bayer (Cardiovascular Division) is listed as a broad incumbent.
Does Cardiome Pharma have an API?
No public API is recorded for Cardiome Pharma.